345 related articles for article (PubMed ID: 32915563)
1. Repurposing of Drugs-The Ketamine Story.
Das J
J Med Chem; 2020 Nov; 63(22):13514-13525. PubMed ID: 32915563
[TBL] [Abstract][Full Text] [Related]
2. [Ketamine for treatment of acute depression].
Hjerrild S; Bjerre J; Pedersen RH; Videbech P
Ugeskr Laeger; 2013 Sep; 175(37):2090-3. PubMed ID: 24011203
[TBL] [Abstract][Full Text] [Related]
3. An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine.
De Berardis D; Tomasetti C; Pompili M; Serafini G; Vellante F; Fornaro M; Valchera A; Perna G; Volpe U; Martinotti G; Fraticelli S; Di Giannantonio M; Kim YK; Orsolini L
Curr Top Med Chem; 2020; 20(7):554-584. PubMed ID: 32003691
[TBL] [Abstract][Full Text] [Related]
4. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
[TBL] [Abstract][Full Text] [Related]
5. Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.
Kadriu B; Musazzi L; Henter ID; Graves M; Popoli M; Zarate CA
Int J Neuropsychopharmacol; 2019 Feb; 22(2):119-135. PubMed ID: 30445512
[TBL] [Abstract][Full Text] [Related]
6. Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression.
Drewniany E; Han J; Hancock C; Jones RL; Lim J; Nemat Gorgani N; Sperry JK; Yu HJ; Raffa RB
J Clin Pharm Ther; 2015 Apr; 40(2):125-30. PubMed ID: 25545040
[TBL] [Abstract][Full Text] [Related]
7. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
8. The Ketamine Antidepressant Story: New Insights.
Alshammari TK
Molecules; 2020 Dec; 25(23):. PubMed ID: 33297563
[TBL] [Abstract][Full Text] [Related]
9. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
Hashimoto K
Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
[TBL] [Abstract][Full Text] [Related]
10. Promises and concerns regarding the use of ketamine and esketamine in the treatment of depression.
Pérez-Esparza R; Kobayashi-Romero LF; García-Mendoza AM; Lamas-Aguilar RM; Fonseca-Perezamador A
Acta Psychiatr Scand; 2019 Aug; 140(2):182-183. PubMed ID: 31251388
[No Abstract] [Full Text] [Related]
11. Ketamine for depression clinical issues.
Iqbal SZ; Mathew SJ
Adv Pharmacol; 2020; 89():131-162. PubMed ID: 32616205
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of ketamine action as an antidepressant.
Zanos P; Gould TD
Mol Psychiatry; 2018 Apr; 23(4):801-811. PubMed ID: 29532791
[TBL] [Abstract][Full Text] [Related]
13. Ketamine's antidepressant action: beyond NMDA receptor inhibition.
Hashimoto K
Expert Opin Ther Targets; 2016 Nov; 20(11):1389-1392. PubMed ID: 27646666
[TBL] [Abstract][Full Text] [Related]
14. Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling.
Gilbert JR; Yarrington JS; Wills KE; Nugent AC; Zarate CA
Int J Neuropsychopharmacol; 2018 Aug; 21(8):740-747. PubMed ID: 29668918
[TBL] [Abstract][Full Text] [Related]
15. What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.
Strasburger SE; Bhimani PM; Kaabe JH; Krysiak JT; Nanchanatt DL; Nguyen TN; Pough KA; Prince TA; Ramsey NS; Savsani KH; Scandlen L; Cavaretta MJ; Raffa RB
J Clin Pharm Ther; 2017 Apr; 42(2):147-154. PubMed ID: 28111761
[TBL] [Abstract][Full Text] [Related]
16. A pivot from synaptic monoamine processes to further downstream processes: The impact of ketamine research.
Steelman BC
Perspect Psychiatr Care; 2019 Apr; 55(2):190-193. PubMed ID: 30040131
[TBL] [Abstract][Full Text] [Related]
17. Evidence that Subanesthetic Doses of Ketamine Cause Sustained Disruptions of NMDA and AMPA-Mediated Frontoparietal Connectivity in Humans.
Muthukumaraswamy SD; Shaw AD; Jackson LE; Hall J; Moran R; Saxena N
J Neurosci; 2015 Aug; 35(33):11694-706. PubMed ID: 26290246
[TBL] [Abstract][Full Text] [Related]
18. Antagonism at the NR2B subunit of NMDA receptors induces increased connectivity of the prefrontal and subcortical regions regulating reward behavior.
Gass N; Becker R; Sack M; Schwarz AJ; Reinwald J; Cosa-Linan A; Zheng L; von Hohenberg CC; Inta D; Meyer-Lindenberg A; Weber-Fahr W; Gass P; Sartorius A
Psychopharmacology (Berl); 2018 Apr; 235(4):1055-1068. PubMed ID: 29305627
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.
Hashimoto K
Biochem Pharmacol; 2020 Jul; 177():113935. PubMed ID: 32224141
[TBL] [Abstract][Full Text] [Related]
20. Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.
Miller OH; Moran JT; Hall BJ
Neuropharmacology; 2016 Jan; 100():17-26. PubMed ID: 26211972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
